The NYKET Center Europe is the first clinic in Europe to provide ketamine infusion services to people with treatment-resistant depression. Breakthrough ketamine treatments have shown to be effective for treatment-resistant conditions and the medical center helps people overcome their symptoms one infusion at a time. Conditions they treat include fibromyalgia, migraines, and complex regional pain syndrome.
Interested in joining a Psychedelics Clinical Trial? Sign up here now and we will connect you with a clinical trial in your area when one becomes available.
The clinic’s highly trained staff is advised by Dr. Glen Brooks, one of the world’s leading experts on the use of ketamine for mental health disorders. The NYKET Center Europe is led by the highly talented Dr. José Miguel Goana. He and the compassionate and experienced team at the clinic understand just how debilitating depression can be.
Their main goal is to help patients heal in a lasting way so they can regain control over their health. By combining cutting-edge science with traditional forms of care, the center hopes to give patients lasting results through the use of ketamine therapy.
Ketamine IV infusion therapy is the most common form of ketamine treatment. The drug is administered directly into the bloodstream through an intravenous drip into the arm. During the treatment, the patient lies still in a calm setting. The effect is usually immediate and can last weeks.
Patients typically receive a series of six infusions over two to three weeks. Most treatments last, on average, two hours. This is what’s called the “induction phase” of the treatment. A doctor monitors the patient’s response to the treatment. The patient stops treatment if the first phase is not effective. The patient moves onto the “maintenance phase” if he or she shows signs of improvement. At this stage patients typically return for one infusion every two to six weeks. At this point, the treatment can last as long as the patient desires and shows improvement.
Discover more Ketamine Clinics in Europe
Leave a Reply